ZIOPHARM, Inc. Seeks Lower Cancer Drug Prices

Published: Jun 02, 2011

Ziopharm Oncology Inc's Chief Executive Jonathan Lewis has an idea that could shake up the biotechnology business -- produce less expensive new cancer drugs.

Recent advances in cancer treatment typically come with eye-popping price tags for therapies that may offer only a few months of extra life. For example, Bristol-Myers Squibb Co's Yervoy for advanced melanoma runs $120,000 for a four-infusion course of treatment. Dendreon Corp's Provenge for advanced prostate cancer costs about $93,000.

Back to news